Publications by authors named "Danilo Rocco"

Claim this Profile
E
Effectiveness of Atezolizumab in Addition to Chemotherapy in ES-SCLC: A Retrospective Real-World Monocentric Study.
Raffaella Pagliaro, Fabiana Vitiello, Marina Gilli, Antonio d'Orologio, Luca Borgese, Danilo Rocco

Cancers (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant therapy of NSCLC: a review of the use and impact of monoclonal antibodies.
Danilo Rocco, Luigi Della Gravara, Cristina Boccia, Cesare Gridelli

Expert Opin Biol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Alessio Cortellini, Valentina Santo, Leonardo Brunetti, Edoardo Garbo, David J Pinato, Danilo Rocco

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls.
Gianluca Russo, Claudia Scimone, Lucia Palumbo, Giuseppina Roscigno, Claudia Sarracino, Danilo Rocco

Crit Rev Oncol Hematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of sotorasib clinical efficacy in KRAS-mutated non-small-cell lung cancer.
Ferdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, David S Hong, Herve Lena, Danilo Rocco

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify Mutation Profiler.
Francesco Pepe, Gianluca Russo, Nadia Barraco, Marco Bono, Angela Listì, Danilo Rocco

Oncol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Interconnection Between UbcH10, p53, and EGFR in Lung Cancer Cells and Their Involvement in Treatment Response.
Cristina Quintavalle, Umberto Malapelle, Marco De Martino, Danilo Rocco, Alfredo Fusco

Genes (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.
Francesco Gelsomino, Luca Boni, Marcello Tiseo, Serena Ricciardi, Danilo Rocco

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant immunotherapy for lung cancer and hilar fibrosis during thoracoscopic lobectomy: Can we improve postoperative outcomes?
Dario Amore, Dino Casazza, Umberto Caterino, Danilo Rocco, Carlo Bergaminelli

Ann Thorac Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy.
Pasquale Pisapia, Antonino Iaccarino, Caterina De Luca, Francesco Pepe, Gianluca Russo, Danilo Rocco

Pathologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.
Danilo Rocco, Luigi Della Gravara, Giovanni Palazzolo, Cesare Gridelli

Curr Med Chem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid biopsy for lung cancer: A cross section on the diagnostic routine experience of a referral Italian institution.
Caterina de Luca, Gianluca Russo, Mariantonia Nacchio, Maria Ingenito, Lucia Palumbo, Danilo Rocco

J Liq Biopsy· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
Danilo Rocco, Luigi Della Gravara, Angela Ragone, Luigi Sapio, Silvio Naviglio

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer.
Danilo Rocco, Luigi Della Gravara, Ciro Battiloro, Giovanni Palazzolo, Cesare Gridelli

Expert Opin Biol Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Danilo Rocco, Luigi Sapio, Luigi Della Gravara, Silvio Naviglio, Cesare Gridelli

Int J Mol Sci· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
Giuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, Valerio Gristina, Elio Gregory Pizzutilo, Danilo Rocco

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of antiangiogenic monoclonal antibodies combined to EGFR-TKIs in the treatment of advanced non-small cell lung cancer with activating EGFR mutations: acquired resistance mechanisms and strategies to overcome them.
Danilo Rocco, Luigi Della Gravara, Giovanni Palazzolo, Cesare Gridelli

Cancer Drug Resist· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center.
Caterina De Luca, Francesco Pepe, Pasquale Pisapia, Antonino Iaccarino, Luisella Righi, Danilo Rocco

Per Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report.
Cristiano Cesaro, Umberto Caterino, Fabio Perrotta, Umberto Masi, Alessandra Cotroneo, Danilo Rocco

Monaldi Arch Chest Dis· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: where do we stand and where are we going?
Danilo Rocco, Luigi Della Gravara, Nicola Franzese, Paolo Maione, Cesare Gridelli

Expert Rev Anticancer Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients.
Umberto Malapelle, Sara Pilotto, Maria Lucia Reale, Francesco Passiglia, Pasquale Pisapia, Danilo Rocco

Crit Rev Oncol Hematol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The treatment of advanced lung adenocarcinoma with activating EGFR mutations.
Danilo Rocco, Luigi Della Gravara, Ciro Battiloro, Paolo Maione, Cesare Gridelli

Expert Opin Pharmacother· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment.
Andrea Bianco, Vito D'Agnano, Maria Gabriella Matera, Luigi Della Gravara, Fabio Perrotta, Danilo Rocco

Expert Rev Respir Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
Sebastiano Buti, Melissa Bersanelli, Fabiana Perrone, Sergio Bracarda, Massimo Di Maio, Danilo Rocco

Eur J Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Alessio Cortellini, Massimo Di Maio, Olga Nigro, Alessandro Leonetti, Diego L Cortinovis, Danilo Rocco

J Immunother Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis